Wellington Management Group LLP Adverum Biotechnologies, Inc. Transaction History

Wellington Management Group LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $8.32 Million - $26.1 Million	-2,475,331 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $1.92 Million - $2.98 Million	-207,484 Reduced 7.73%	2,475,331 $24.4 Million
Q4 2020 Feb 12, 2021	BUY	$9.84 - $14.26 $4.02 Million - $5.82 Million	408,224 Added 17.95%	2,682,815 $29.1 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $10.7 Million - $22.4 Million	1,035,231 Added 83.53%	2,274,591 $23.4 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $10.6 Million - $31.8 Million	1,239,360 New	1,239,360 $25.9 Million
Q1 2020 May 14, 2020	SELL	$7.98 - $16.32 $1.94 Million - $3.96 Million	-242,609 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$5.12 - $12.22 $1.24 Million - $2.96 Million	242,609 New	242,609 $2.8 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.